First, we analyzed the sIFNAR2 serum levels in a follow up study of two independent cohorts of MS patients and observed an increase of sIFNAR2 levels after 6 months of IFN-β administration in both cohorts. Here, IFNB1 is linked to myeloid sarcoma.